Last reviewed · How we verify
Infection by Campylobacter fetus — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Minocycline Hydrochloride | MINOCYCLINE | Rempex | Tetracycline-class Drug | 1971-01-01 | ||
| Minocyclin | Minocyclin | University of Southern California | 30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Rempex · 1 drug in Infection by Campylobacter fetus
- University of Southern California · 1 drug in Infection by Campylobacter fetus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Infection by Campylobacter fetus:
- Infection by Campylobacter fetus treatment updates — RSS
- Infection by Campylobacter fetus treatment updates — Atom
- Infection by Campylobacter fetus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Infection by Campylobacter fetus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-by-campylobacter-fetus. Accessed 2026-06-10.
Related
- Infection by Campylobacter fetus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing